4.22
price down icon0.47%   -0.02
after-market アフターアワーズ: 4.23 0.01 +0.24%
loading
前日終値:
$4.24
開ける:
$4.35
24時間の取引高:
6.07M
Relative Volume:
0.98
時価総額:
$912.27M
収益:
$76.20M
当期純損益:
$-17.37M
株価収益率:
463.74
EPS:
0.0091
ネットキャッシュフロー:
$-75.81M
1週間 パフォーマンス:
-4.09%
1か月 パフォーマンス:
-26.99%
6か月 パフォーマンス:
+48.59%
1年 パフォーマンス:
+586.07%
1日の値動き範囲:
Value
$4.08
$4.47
1週間の範囲:
Value
$4.08
$5.15
52週間の値動き範囲:
Value
$0.40
$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1114)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
69
Name
Twitter
@cytomxinc
Name
次回の収益日
2026-03-16
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CTMX icon
CTMX
Cytomx Therapeutics Inc
4.22 916.59M 76.20M -17.37M -75.81M 0.0091
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 アップグレード JP Morgan Neutral → Overweight
2026-01-20 開始されました Guggenheim Buy
2025-09-22 開始されました Cantor Fitzgerald Overweight
2025-09-17 再開されました Barclays Overweight
2025-07-31 開始されました Oppenheimer Outperform
2025-05-15 アップグレード H.C. Wainwright Neutral → Buy
2025-04-14 再開されました Piper Sandler Overweight
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Mar 24, 2026

Jefferies reiterates Buy rating on CytomX stock after phase 1 data - Investing.com Canada

Mar 24, 2026
pulisher
Mar 23, 2026

CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

CTMX: Piper Sandler Raises Price Target to $12 | CTMX Stock News - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

Piper Sandler raises CytomX stock price target on drug trial data - Investing.com Canada

Mar 23, 2026
pulisher
Mar 22, 2026

CytomX Therapeutics launches $250M public offering - MSN

Mar 22, 2026
pulisher
Mar 21, 2026

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data - AOL.com

Mar 21, 2026
pulisher
Mar 21, 2026

How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - Sahm

Mar 21, 2026
pulisher
Mar 20, 2026

A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Insider Monkey

Mar 20, 2026
pulisher
Mar 20, 2026

CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN

Mar 20, 2026
pulisher
Mar 20, 2026

CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits

Mar 20, 2026
pulisher
Mar 20, 2026

Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

CTMX Stock Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Sean McCarthy, CytomX Therapeutics CEO, sells $764k in stock By Investing.com - Investing.com Canada

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX therapeutics (CTMX) chief medical officer sells $136k in stock - Investing.com Canada

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics SVP Belvin sells $202k in stock By Investing.com - Investing.com Australia

Mar 19, 2026
pulisher
Mar 19, 2026

Ogden, CytomX Therapeutics CFO, sells $124k in shares - Investing.com

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics (CTMX) reports Q4 loss, misses revenue estimates - MSN

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks

Mar 19, 2026
pulisher
Mar 19, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday? - Sahm

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus

Mar 19, 2026
pulisher
Mar 18, 2026

Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka

Mar 18, 2026
pulisher
Mar 18, 2026

Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

CTMX: Key Managers in Recent Offering - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures - The Globe and Mail

Mar 18, 2026

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):